Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis

NCT07898774 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07898774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 3
Overall status
Recruiting
Start date
January 21, 2027
Completion date
January 17, 2031
Enrollment
30 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulopathy (c3g), primary immune-complex membranoproliferative glomerulonephritis (ic-mpgn), recurrent glomerular disease after kidney transplantation

Arms

As registered; 1 arm.

  • Pegcetacoplan ExperimentalPegcetacoplan

    Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Occurrence of Clinically Significant Recurrent Disease Within 2 years after kidney transplantation

    Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy

Lead sponsor's other trials

Swedish Orphan Biovitrum, most recent start first.